Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists

Journal of Peptide Science

Volumn 5, Issue 11, 1999, Pages 472-490

  Manning, Maurice ^a   Stoev, Stoytcho ^a   Cheng, Ling Ling ^a   Nga Ching, W O ^b   Chan, W Y ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hypotensive; Vasodepressor; Vasopressin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGIPRESSIN DERIVATIVE; RECEPTOR SUBTYPE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; VASODILATATION;

ARGININE VASOPRESSIN; HYPOTENSION; MOLECULAR STRUCTURE; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS; VASOPRESSINS;

EID: 0032758539     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1387(199911)5:11<472::AID-PSC217>3.0.CO;2-A     Document Type: Article

References (79)

1. Manning M, Olma A, Klis WA, Kolodziejczyk A, Seto J, Sawyer WH. Design of more potent antagonists of the antidiuretic response to arginine-vasopressin. J. Med. Chem. 1982; 25: 45-50.
2. Manning M, Stoev S, Wo NC, Chan WY. Discovery of novel selective hypotensive analogues of a vasopressin antagonist. In Peptides 1996, Ramage R, Epton R (eds). Mayflower Scientific Ltd.: UK, 1998; 615-616.
3. Chan WY, Wo NC, Stoev S, Cheng L-L, Manning M. Discovery of novel selective hypotensive vasopressin peptides: a new vasodilating vasopressin receptor? In Vasopressin and Oxytocin: Molecular, Cellular and Clinical Research, Zingg HH, Bichet DC, Bourque C (eds). Adv. Exptl. Med. Biol. 1998; 449: 451-453.
4. Chan WY, Wo NC, Stoev S, Cheng L-L, Manning M. Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors. Br. J. Pharmacol. 1998; 125: 803-811.
5. Katusic ZS, Sheperd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ. Res. 1984; 55: 575-579.
6. 2 receptor. J. Clin. Invest. 1989; 84: 418-426.
7. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998; 156: 223-229.
8. Kruszynski M, Lammek B, Manning M, Seto J, Haldar J, Sawyer WH. [1-(β-Mercapto-β,β-cyclopentamethylenepropionic acid, 2-(O-methyl) tyrosine] arginine-vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid] arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 1980; 23: 364-368.
9. 2 vasopressin antagonists with structural changes at their C-terminals. Peptides 1988; 9: 157-163.
10. Manning M, Stoev S, Cheng L-L, Wo NC, Chan WY. Discovery and design of novel vasopressin hypotensive peptide agonists. J. Receptor Signal Transduction Res. 1999; 19(1-4): 631-644.
11. Manning M, Przybylski JP, Klis WA, Kruszynski M, Olma A, Wo NC, Pelton GH, Sawyer WH. Cyclic conformation is not required for binding of antagonists to vasopressin receptors. Nature 1987; 329: 839-840.
12. 1a receptor) responses to vasopressin. J. Med. Chem. 1990; 33: 3079-3086.
13. Stoev S, Cheng L-L, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally restricted, polar and charged amino acids. J. Peptide Sci. 1999; 5: 141-153.
14. du Vigneaud V. An organic chemical approach to the study of the significance of the chemical functional groups of oxytocin to its biological activities. In Proceedings of the Robert A. Welch Foundation Conferences on Chemical Research. VIII. Selected Topics in Modern Biochemistry. Houston, TX, 1964; 133-147.
15. Berde B, Boissonnas RA. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. In Neurohypophysial Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology, vol. 23, Berde B (ed.). Springer Verlag: Berlin, 1968; 802-870.
16. Rudinger J. The design of peptide hormone analogs. In Ariens Drug Design, vol 2. Academic Press: New York, 1971; 319-419.
17. Manning M, Lowbridge J, Haldar J, Sawyer WH. Design of neurohypophysial peptides which exhibit selective agonistic and antagonistic properties. Federation Proc. 1977; 36: 1848-1852.
18. Sawyer WH, Grzonka Z, Manning M. Neurohypophysial peptides: design of tissue-specific agonists and antagonists. Molec. Cell. Endocrinol. 1981; 22: 117-134.
19. Manning M, Bankowski K, Sawyer WH. Selective agonists and antagonists of vasopressin. In Vasopressin, Principles and Properties, Gash DM, Boer GJ (eds). Plenum Press: New York, 1987; 335-368.
20. Hruby VJ, Smith CW. Structure-activity relationships of neurohypophysial peptides. In The Peptides, vol. 8, Udenfriend S, Meienhofer J (eds). Academic Press: Orlando, FL, 1987; 77-207.
21. Lebl M, Jost K, Brtnik F. Tables of analogs. In Handbook of Neurohypophysial Hormone Analogs, vol. 2, part 2, Jost K, Lebl M, Brtnik F (eds). CRC Press: Boca Raton, FL, 1987; 127-267.
22. Kinter LB, Huffman WF, Stassen FL. Antagonists of the antidiuretic activity of vasopressin. Am. J. Physiol. 1988; 254: F165-F177.
23. Manning M, Sawyer WH. Discovery, development and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 1989; 114: 617-632.
24. Manning M, Sawyer WH. Design, synthesis and some uses of receptor specific agonists and antagonists of vasopressin and oxytocin. J. Receptor Res. 1993; 13: 195-214.
25. Manning M, Cheng L-L, Klis WA, Stoev S, Przybylski J, Bankowski K, Sawyer WH, Barberis C, Chan WY. Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. In Oxytocin: Cellular and Molecular Approaches in Medicine and Research, Ivell R, Russel J (eds). Plenum Press: New York, 1995; 559-583.
26. Manning M, Cheng L-L, Stoev S, Sawyer WH, Tribollet E, Barberis C, Wo NC, Chan WY. Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, Saito T, Kurokawa K, Yoshido S (eds). Elsevier: Amsterdam, 1995; 21-38.
27. Manning M, Lammek B, Kolodziejczyk A, Seto J, Sawyer WH. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine vasopressin. J. Med. Chem. 1981; 24: 701-706.
28. Bankowski K, Lammek B, Kruszynski M, Manning M, Seto J, Sawyer WH. 2-O-methyl and 2-O-ethyl-tyrosine derivatives of [8-arginine] vasopressin analogs: highly specific antidiuretic agonists. Coll. Czech. Chem. Commun. 1988; 53: 2617-2626.
29. Lammek B, Bankowski K, Misicka A, Manning M, Seto J, Sawyer WH. 2-O-Alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: Highly specific and potent antidiuretic agonists. J. Med. Chem. 1989; 32: 244-247.
30. Manning M, Olma A, Klis WA, Seto J, Sawyer WH. Potent antagonists of the antidiuretic response to arginine-vasopressin based on modifications of [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid), 2-D-phenylalanine, 4-valine] arginine-vasopressin at position 4. J. Med. Chem. 1983; 26: 1607-1613.
31. Manning M, Nawrocka E, Misicka A, Olma A, Klis WA, Seto J, Sawyer WH. Potent and selective antagonists of the antidiuretic response to arginine-vasopressin based on modifications of [1-β-mercapto-β,β-pentamethylenepropionic acid), 2-D-isoleucine, 4-valine]arginine-vasopressin at position 4. J. Med. Chem. 1984; 27: 423-429.
32. Proux JP, Miller CA, Li JP, Carney RL, Girardie A, Delaage M, Schooley DA. Identification of an arginine vasopressin-like diuretic hormone from Locusta migratoria. Biochem. Biophys. Res. Commun. 1987; 149: 180-186.
33. Cruz LJ, de Santos V, Zafaralla GC, Ramilo CA, Zeikus R, Gray WR, Olivera BM. Invertebrate vasopressin/oxytocin homologs: characterization of peptides from Conus Geographus and Conus Striatus Venoms. J. Biol. Chem. 1987; 262: 15821-15824.
34. Kruszynski M, Manning M, Wo NC, Sawyer WH. Invertebrate neuropeptides resembling vasotocin and some analogues: Synthesis and pharmacological properties. Experientia 1990; 46: 771-773.
35. 4]arginine-vasopressin and two related analogues. Acta Chemica Scandinavian B 1985; 39: 453-457.
36. 2 antagonists containing arginine in the 4-position. Experientia 1991; 47: 83-86.
37. Cort JH, Fric I, Carlsson L, Gillessen D, Bystrický S, Škopková J, Gut V, Studer RO, Mulder JL, Bláha K. Biological and chiroptical sequelae of graded alkyl substitutions in the vasopressin ring. Mol. Pharmacol. 1976; 12: 313.
38. Plis̄ka V, Melin P, Carlsson L. 4-Substituted analogs of deamino-D-arginine-vasopressin: biological potencies and structure-activity relationships related to position 4. In Peptides: Synthesis. Structure, Function, Proceedings of the 7th American Peptide Symposium, Rich HD, Gross E (eds). Pierce Chemical: Rockford, IL, 1981; 717-720.
39. Gazis D, Schwartz IL, Lammek B, Grzonka Z. Influence of sarcosine or N-methylalanine in position 7 on the antagonistic properties of [1-deaminopenicillamine]-and [1-(β-mercapto-β,β-cyclopentamethylene-propionic acid)]-vasopressin. Int. J. Peptide Protein Res. 1984; 28: 78-83.
40. Ali FE, Bryan W, Chang H, Huffman WF, Moore ML, Heckman G, Kinter LB, McDonald J, Schmidt D, Ashton-Shue D, Stassen FL. Potent vasopressin antagonists lacking the proline residue at position 7. J. Med. Chem. 1986; 29: 984-988.
41. 2 antagonists of arginine vasopressin (AVP). In Peptides 1986, Theodoropoulas D (ed.). Walter de Gruyter: Berlin, 1987; 459-463.
42. Grzonka Z, Lammek B, Kasprzykowski F, Gazis D, Schwartz L. Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7. J. Med. Chem. 1983; 26: 555-559.
43. Glass JD, du Vigneaud V. Solid-phase synthesis and pressor potency of [1-deamino-9-ethylenediamine]-lysine-vasopressin. J. Med. Chem. 1973; 16: 160-161.
44. 1 -receptor) response to arginine-vasopressin. J. Med. Chem. 1992; 35: 382-388.
45. Manning M, Kruszynski M, Bankowski K, Olma A, Lammek B, Cheng L-L, Klis WA, Seto J, Haldar J, Sawyer WH. Solid phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem. 1989; 32: 382-391.
46. Zaoral M, Kolc J, Šorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Coll. Czech. Chem. Commun. 1967; 32: 1250-1257.
47. Manning M, Balaspiri L, Acosta M, Sawyer WH. Solid-phase synthesis of [1-deamino-4-valine]-8-D-arginine-vasopressin (DVDAVP). A highly potent and specific antidiuretic agent possessing protracted effects. J. Med. Chem. 1973: 16: 975-978.
48. Sawyer WH, Acosta M, Balaspiri L, Manning M. Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. Endocrinology 1974; 94: 1106-1115.
49. du Vigneaud V, Lawler HC, Popenoe EA. Enzymatic cleavage of glycinamide from vasopressin and proposed structure for the pressor-antidiuretic hormone of the posterior pituitary. J. Am. Chem. Soc. 1953; 75: 4880-4881.
50. Walter R, Havran RT, Schwartz IL. Synthetic metabolites of neurohypophyseal hormones [des-9-glycinamide] oxytocin and [des-9-glycinamide,des-8-leucine] oxytocin. J. Med. Chem. 1976; 19: 328-330.
51. Manning M, Olma A, Klis W, Kolodziejczyk A, Nawrocka E, Misicka A, Seto J, Sawyer WH. Carboxy terminus of vasopressin required for activity but not binding. Nature 1984; 308: 652-653.
52. 1) receptors. J. Med. Chem. 1987; 30: 2245-2252.
53. Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng L-L, Chan WY, Wo NC, Sawyer WH. Vasopressin antagonists with C-terminal ethylenediamine-linked retro amino acids. J. Med. Chem. 1992; 35: 3895-3904.
54. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963; 85: 2149-2154.
55. Merrifield RB. Solid-phase peptide synthesis. III. An improved synthesis of bradykinin. Biochemistry 1964; 3: 1385-1390.
56. Stewart JM, Young JD. Solid phase Peptide Synthesis. Pierce Chemical Company; Rockford, IL, 1984.
57. Manning M, Stoev S, Cheng L-L, Wo NC, Chan WY. Exploring the structure/function relationships of novel vasopressin hypotensive peptides. In Peptides 1998, Bajusz S, Hudecz F (eds). Akademic Kiadô: Budapest, Hungary, 1999; 56-57.
58. Koenig W, Geiger R. New method for the synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxy-benzotriazole as additives. Chem. Ber. 1970; 103: 788-798.
59. Manning M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 1968; 90: 1348-1349.
60. Manning M, Cheng L-L, Stoev S, Klis WA, Nawrocka E, Olma A, Sawyer WH, Wo NC, Chan WY. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. J. Peptide Sci. 1997; 3: 31-46.
61. Bodanszky M, du Vigneaud V. A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. J. Am. Chem. Soc. 1959; 81: 5688-5691.
62. Bodanszky M, Sheehan JT. Active esters and resins in peptide synthesis. Chem. Ind. 1964; 1423-1424.
63. du Vigneaud V, Gish DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 1954; 76: 4751-5752.
64. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J. Am. Chem. Soc. 1954; 76: 3115-3121.
65. Hope DV, Murti VVS, du Vigneaud V. A highly potent analogue of oxytocin, desamino-oxytocin. J. Biol. Chem. 1962; 237: 1563-1566.
66. Rivier J, Kaiser R, Galyean R. Solid phase synthesis of somatosatatin and glucagon-selective analogs in gram quantities. Biopolymers 1978; 17, 1927-1938.
67. Manning M, Wuu TC, Baxter JWM. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 1968; 38: 396-398.
68. Dekanski J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952; 7: 567-572.
69. Sawyer WH. Biologic assays for oxytocin and vasopressin. Methods Med. Res. 1961; 9: 210-219.
70. Munsick RA. Effect of magnesium ion on the response of the rat uterus to neurohypophysical hormones and analogues. Endocrinology 1960; 66: 451-457.
71. Holton P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948; 3: 328-334.
72. Schild HO. pA, a new scale of the measurement of drug antagonism. Br. J. Pharmacol Chemother. 1958; 2: 189-206.
73. Dyckes DF, Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-mercaptoβ,β-diethyl-propionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin. J. Med. Chem. 1974; 17: 250-252.
74. Manning M, Coy EJ, Sawyer WH, Acosta M. Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J. Med. Chem. 1973; 16: 463-466.
75. Gisin, BF. The preparation of Merrifield-resins through total esterification with cesium salts. Helv. Chim. Acta 1973; 56: 1476-1482.
76. Kolodziejczyk AM, Manning M. A convenient method for O-alkylation of N-substituted tyrosines using a crown ether. J. Org. Chem. 1981; 46: 1944-1946.
77. Nestor JJ Jr, Ferger MF, du Vigneaud V. [1-β-mercapto-β,β-pentamethylenepropionic acid) oxytocin, a potent inhibitor of oxytocin. J. Med. Chem. 1975; 18: 284-287.
78. Castro B, Dormoy JR, Evin G, Selve C. Reactifs de couplage peptidique. IV. (1)-l'hexafluorophosphate de benzotriazolyl N-oxytris-dimethylamino phosphonium (B.O.P.). Tetrahedron Lett. 1975; 14: 1219-1222.
79. Castro B, Dormoy JR, Evin G, Selve C. B.O.P.: A new peptide coupling reagent exemplified in the synthesis of somatostatin. In Peptides 1976, Loffet A (ed.). Editions de L'Universite de Bruxelles: 1976; 79-83.